

# Immunology House Keeping and Admin 13 | 23/05/2022

## Staffing

- a) Lynsey leave 2<sup>nd</sup> week of June. Sherly to fill shifts on Mon/Tues if enough staff in Haem.

## Changes to existing tests or requests for changes

- a)

## New Tests or equipment

- a) 30-300uL multichannel pipette battery not charging. Tested with other charger and powerpoint. Bought in 2006. Steve-OK to buy new multichannel pipette.

## Quality Assurance

- a) Riskman, who is responsible? CSP brought me a result to be withdrawn due to mix up of accession labels on a tryptase sample. Steve- CSP to raise Riskman in this case. I have withdrawn result and phoned St Vincents, and asked Craig
- b) Discordant result RCPA QAP TIgE. Checked entry, Requested report from Abacus dx to investigated if patient samples were affected by errors on 2 runs, including RCPA QAP run. Abacus were unable to determine cause of out of range result. Rerun on same analyser was in range. One patient sample was affected. To withdraw result and raise IQAP.
- c) NATA- Updating methods.
- d) Internal Audit next week with Chewe- Reagents, methods, etc.

## Stock / Inventory

- a) Asparaginase PEG controls and std batch lasted only 5 months. Usually lasts 12 months. Another new production day required. Steve suggested contacting manufacturer to see if we can be supplied with the drug directly for production, rather than requesting from RCH. Mayumi to contact Servier, producer of Oncaspar in Australia.

## IT issues / Network Issues

- a) Lynsey still has not received reimbursement for Multimer tanks.

## Projects / Trials

- a) Plate reader validation ongoing. F8BA requires more data and understanding
- b) Multimer caught up as of today's run. Need to restart conversation about where testing will go if multimer tanks fail again. To bring up at rolling meeting this Thursday.
- c) Validation report progressing well. Julian has been away. Will be in this week to talk about how to proceed with analysis of results. Julian not happy with Phadia 250 RNP, SCL-70 and Sm results. To follow up with IT about request for new/change of test request.
- d) Centromere is a new antigen in ENA characterisation. Centromere may have to be omitted from testing after ENA characterisation validation is approved, and validated on its own with samples from Anat Path. These have been requested. Mayumi to check who else does ENA characts on Phadia and Evolis analysers.

## Attendee list

Steve Schischka, Mayumi Knight, Lynsey Peach